PSA Levels and Biopsy Samples After Implant Radiation and Hormone Therapy in Patients With Stage I or Stage II Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed prostate cancer
• * Previously untreated disease prior to participation on protocol JUSMH-BRI-GU05-01
• Intermediate-risk disease as defined by the following:
• * Clinical stage \< T2c
• * Prostate-specific antigen (PSA) ≤ 20 ng/mL
• * Gleason score \< 8
• Previously enrolled on protocol JUSMH-BRI-GU05-01
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-1
• Life expectancy ≥ 3 months
• WBC ≥ 2,000/μL
• Hemoglobin ≥ 10.0 g/dL
• Platelet count ≥ 100,000/μL
• Serum creatine level ≤ 2.0 mg/dL
• ALT and AST ≤ 100 IU/L
• No other cancer requiring treatment
• No poorly controlled hypertension (i.e., diastolic blood pressure ≥ 120 mm Hg)
• No severe psychiatric disorders, including schizophrenia or dementia
• No poorly controlled diabetes
• Considered appropriate for study participation, as determined by the Principal Investigator or Clinical Investigator
• PRIOR CONCURRENT THERAPY:
• No prior drugs for benign prostatic hyperplasia (other than antiandrogen therapy)
• No prior surgery for prostate cancer
• No concurrent steroid drugs (except for ointment)
• No other concurrent antiandrogen therapy